lunes, 10 de diciembre de 2012

Drug Safety and Availability FDA Drug Safety Communication: 5-alpha reductase inhibitors (5-ARIs) may increase the risk of a more serious form of prostate cancer

Drug Safety and Availability FDA Drug Safety Communication: 5-alpha reductase inhibitors (5-ARIs) may increase the risk of a more serious form of prostate cancer
Publicado por en

No hay comentarios.:

Publicar un comentario

Suscribirse a: Comentarios de la entrada (Atom)

clitorisvaginavejigasalud

Bookmark and Share

hormonas yosteoporosis en el hombre

Bookmark and Share